What is the clinical evidence from this study?

Study design: Other. Intervention: Albunex (sonicated albumin microspheres). Primary outcome: Cavity opacification greater than or equal to +2 in the right ventricle.

July 23, 2026Journal of the American College of Cardiology

Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results

View Full Paper

Ask AI

Bookmark

Key result

Intravenous Albunex safely achieves significant right ventricular opacification in ~88% of injections.

n=71

Why the study?

Does intravenous sonicated albumin microspheres safely provide ventricular cavity opacification during echocardiography?

Population

71 patients at three independent medical institutions undergoing two-dimensional echocardiographic examination

Design

Cohort, Efficacy assessed by two independent blinded observers

Follow-up

3 days

Authors

SFSteven B. FeinsteinGeneral Cardiology JCJorge CheirifTexas Health Dallas FCFolkert J. ten CateCedars-Sinai Medical Center

Discussion

Member takes

Implication

Intravenous sonicated albumin microspheres safely and effectively provide right and left ventricular cavity opacification during echocardiography.

Key Points

This study aims to assess the safety and efficacy of a new transpulmonary ultrasound contrast agent across multiple centers.
Multicenter clinical trial design
Evaluation of the contrast agent's safety and efficacy
Inclusion of diverse patient populations across multiple sites.
The new contrast agent demonstrated significant safety with minimal adverse events reported.
Efficacy results indicated improved imaging results compared to standard agents.
Initial findings suggest a favorable profile for clinical use in ultrasound applications.

Structured PICO

Does intravenous sonicated albumin microspheres safely provide ventricular cavity opacification during echocardiography?

Population

71 patients who received three intravenous doses of Albunex and were followed for 3 days to assess safety and echocardiographic contrast efficacy.

Intervention

Three intravenous doses of sonicated albumin microspheres, ranging from 0.01 to 0.12 ml/kg body weight

Outcome

Safety (clinical, laboratory, and electrocardiographic evaluation) and efficacy (ventricular cavity opacification graded 0 to +3 by blinded observers)surrogate

Intravenous sonicated albumin microspheres safely and effectively provide right and left ventricular cavity opacification during echocardiography.

Cite This Study

Feinstein et al. (1990) studied this question. Albunex (sonicated albumin microspheres) was evaluated on Cavity opacification greater than or equal to +2 in the right ventricle. Intravenous Albunex was well tolerated with no serious side effects, achieving right and left ventricular cavity opacification ≥+2 in 88% and 63% of injections, respectively.

synapsesocial.com/papers/6a628544b5a8ea3f4a86bdf8 https://doi.org/10.1016/0735-1097(90)90580-i

View Full Paper

Ask AI

Bookmark

Implication

Intravenous sonicated albumin microspheres safely and effectively provide right and left ventricular cavity opacification during echocardiography.

Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider